News | Prostate Cancer | April 04, 2017

System that combines real-time MRI with transurethral, robotically-driven therapeutic ultrasound employed for the first time in Germany

April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been successfully conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Agron Lumiani, M.D.

TULSA-PRO combines real-time magnetic resonance imaging (MRI) with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. The technology has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favorable safety profile, with low rates of serious or long-term adverse events.

The procedure was administered by Lumiani, founder of the ALTA Klinik, a leading German radiologist and an early adopter of MRI diagnostics and MRI-targeted prostate biopsy. Lumiani intends to leverage TULSA technology for focal therapy in the treatment of patients with localized prostate cancer, and also believes that TULSA-PRO holds promise for ablation in other prostate conditions.

“ALTA was established as a state-of-the-art clinic offering the most innovative diagnostic procedures and treatments,” commented Lumiani. “MRI continues to become a more trusted tool for diagnostics and biopsy of prostate cancer.  Since 2009, the clinic has specialized in MRI diagnostics and MRI-targeted prostate biopsy. Profound’s TULSA-PRO system aligns well with this concept, now enabling treatment under real-time MR guidance and control. TULSA-PRO can complete this paradigm shift, potentially offering patients a therapy that is safe and effective, with minimal side effects. I am optimistic about the technology and look forward to making it available to our patients.”

Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The company is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology. If successful, TACT is expected to support Profound's application to the FDA for approval to market TULSA-PRO in the United States.

For more information: www.profoundmedical.com

Related Content

Videos | Coronavirus (COVID-19)

An example of popliteal artery thrombosis formation caused by COVID-19 (SARS-CoV-2). Coronavirus often caused thrombus ...

Time October 19, 2021
arrow
Videos | Coronavirus (COVID-19)

This is a clinical example of lung ultrasound of a COVID-19 patient showing B-lines and pleural thickening.

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
News | Ultrasound Imaging

October 15, 2021 — NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung, introduces the V8; a high-end ...

Time October 15, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
News | Radiology Imaging

October 6, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), liver stiffness measurements (LSM) ...

Time October 06, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Cardiovascular Ultrasound

October 5, 2021 – UltraSight, a digital health company developing artificial intelligence (AI) enabled cardiac imaging ...

Time October 05, 2021
arrow
News | Ultrasound Imaging

October 5, 2021 — Ultrasound experts urged the health care community to work to expand utilization of ultrasound ...

Time October 05, 2021
arrow
News | Radiology Business

September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software ...

Time September 27, 2021
arrow
Subscribe Now